Max Hodak has named a year for Science Corporation's next retinal implant to reach human trials

Max Hodak, who leads Science Corporation, has put a specific, checkable timeline on what the company’s next retinal implant will do and when. The next version is currently in animal studies, he says, and should enter human trials next year. If that schedule holds, the technology would expand the treatable patient population to millions.

That is the whole claim, stated plainly. It is worth examining both what it would require to be right and what happens to the broader field if it is.

The path from animal studies to approved human use is long, and Hodak’s own framing is appropriately hedged. He says the device “hopefully” reaches humans next year, not that it will. Animal studies can surface problems that delay or fundamentally redirect a program. Results that look promising in preclinical work do not always translate to the same profile in human tissue. Human trials, once begun, generate their own data before any regulatory body evaluates a submission, and that process adds years to even optimistic timelines.

None of that uncertainty makes the call uninteresting. It makes it specific enough to track. Hodak is not gesturing at a decade-long research horizon or a someday vision of what the technology might become. He is describing a program already in animal studies, with a named next step and a named timeframe. That specificity is what gives the prediction its force and what will make it straightforwardly falsifiable within the next year or two.

The next version, which is going to animal studies now, will be in humans hopefully next year. Should expand that to millions. Max Hodak

The scale of the population Hodak is invoking is where the stakes become concrete. Reaching millions of patients would require the device to perform meaningfully for a much broader group than today’s eligible population. That is not a matter of marketing to a larger audience. It requires the device to clear a higher clinical bar across a more varied patient population, and to satisfy regulators in multiple jurisdictions. The jump to millions is a clinical and regulatory claim, not only an engineering one.

What makes Hodak’s timeline worth watching closely is the compounding effect of each stage going right or wrong. If animal studies complete without significant setbacks and the program advances on schedule, the field will begin to see human data within a few years. That data will either support the expansion claim or reveal the gaps between preclinical promise and clinical reality. Either outcome is informative for the broader space of neural and retinal prosthetics, where the question of how far non-biological hardware can substitute for damaged biological systems remains genuinely open.

The commercial infrastructure required to serve millions of patients represents an entirely different scale of manufacturing, surgical training, and post-market surveillance than one serving a narrower population. Science Corporation would have to build much of that infrastructure in parallel with the clinical program, not after it. That parallel burden is not disqualifying, but it is part of the honest accounting of what the prediction requires.

Hodak has named a year. The animal studies are already underway. By the time the next twelve months pass, it will be clear whether the human trial timeline held or slipped, and the field will know considerably more about whether millions is a near-term clinical reality or a further horizon than the current program can sustain.